In our cohort, while OS was significantly shorter in patients with TERT mutation than those without, treatment response and PFS were similar in both groups, suggesting that TERT mutation may not affect the response to combined immunotherapy in HCC. Here, TERT is linked to hepatocellular carcinoma.